ArticleJournal of cancer research and clinical oncology2023

Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.

Jeronimo Rafael Rodriguez-Cid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.